Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Bioadaptives (BDPT) EPS (Basic) (2019 - 2025)

Bioadaptives' EPS (Basic) history spans 7 years, with the latest figure at -$0.07 for Q4 2025.

  • Quarterly results put EPS (Basic) at -$0.07 for Q4 2025, up 37.67% from a year ago — trailing twelve months through Dec 2025 was -$0.15 (down 33.97% YoY), and the annual figure for FY2025 was -$0.13, down 17.94%.
  • EPS (Basic) for Q4 2025 was -$0.07 at Bioadaptives, down from -$0.03 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.0 in Q3 2024 to a low of -$0.12 in Q4 2023.
  • The 5-year median for EPS (Basic) is -$0.0 (2021), against an average of -$0.02.
  • The sharpest move saw EPS (Basic) skyrocketed 98.37% in 2023, then plummeted 105647.06% in 2025.
  • Year by year, EPS (Basic) stood at -$0.0 in 2021, then rose by 1.06% to -$0.0 in 2022, then plummeted by 4467.49% to -$0.12 in 2023, then grew by 8.33% to -$0.11 in 2024, then skyrocketed by 37.67% to -$0.07 in 2025.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$0.07, -$0.03, and -$0.02 for Q4 2025, Q3 2025, and Q2 2025 respectively.